Literature DB >> 33203702

Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway.

Nathan Harmston1,2, Jun Yi Stanley Lim1, Oriol Arqués3, Héctor G Palmer3, Enrico Petretto4, David M Virshup5,6, Babita Madan5.   

Abstract

Aberrant Wnt signaling drives a number of cancers through regulation of diverse downstream pathways. Wnt/β-catenin signaling achieves this in part by increasing the expression of proto-oncogenes such as MYC and cyclins. However, global assessment of the Wnt-regulated transcriptome in vivo in genetically distinct cancers demonstrates that Wnt signaling suppresses the expression of as many genes as it activates. In this study, we examined the set of genes that are upregulated upon inhibition of Wnt signaling in Wnt-addicted pancreatic and colorectal cancer models. Decreasing Wnt signaling led to a marked increase in gene expression by activating ERK and JNK; these changes in gene expression could be mitigated in part by concurrent inhibition of MEK. These findings demonstrate that increased Wnt signaling in cancer represses MAPK activity, preventing RAS-mediated senescence while allowing cancer cells to proliferate. These results shift the paradigm from Wnt/β-catenin primarily as an activator of transcription to a more nuanced view where Wnt/β-catenin signaling drives both widespread gene repression and activation. SIGNIFICANCE: These findings show that Wnt/β-catenin signaling causes widespread gene repression via inhibition of MAPK signaling, thus fine tuning the RAS-MAPK pathway to optimize proliferation in cancer. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33203702     DOI: 10.1158/0008-5472.CAN-20-2129

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Pluripotency Stemness and Cancer: More Questions than Answers.

Authors:  Jiří Hatina; Michaela Kripnerová; Zbyněk Houdek; Martin Pešta; Filip Tichánek
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  The drug-induced phenotypic landscape of colorectal cancer organoids.

Authors:  Johannes Betge; Niklas Rindtorff; Jan Sauer; Benedikt Rauscher; Clara Dingert; Haristi Gaitantzi; Frank Herweck; Kauthar Srour-Mhanna; Thilo Miersch; Erica Valentini; Kim E Boonekamp; Veronika Hauber; Tobias Gutting; Larissa Frank; Sebastian Belle; Timo Gaiser; Inga Buchholz; Ralf Jesenofsky; Nicolai Härtel; Tianzuo Zhan; Bernd Fischer; Katja Breitkopf-Heinlein; Elke Burgermeister; Matthias P Ebert; Michael Boutros
Journal:  Nat Commun       Date:  2022-06-06       Impact factor: 17.694

3.  WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.

Authors:  Amanpreet Kaur; Jun Yi Stanley Lim; Sugunavathi Sepramaniam; Siddhi Patnaik; Nathan Harmston; May Ann Lee; Enrico Petretto; David M Virshup; Babita Madan
Journal:  EMBO Mol Med       Date:  2021-03-04       Impact factor: 12.137

4.  KRAS mutation-independent downregulation of MAPK/PI3K signaling in colorectal cancer.

Authors:  Kuen Kuen Lam; Choong Leong Tang; Emile Tan; Siew Heng Wong; Peh Yean Cheah
Journal:  Mol Oncol       Date:  2022-01-01       Impact factor: 6.603

5.  Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies.

Authors:  Miguel A Ortega; Leonel Pekarek; Oscar Fraile-Martinez; Cielo Garcia-Montero; Miguel A Saez; Angel Asúnsolo; Miguel A Alvarez-Mon; Jorge Monserrat; Lidia Ruiz-Llorente; Natalio García-Honduvilla; Agustin Albillos; Julia Buján; Melchor Alvarez-Mon; Luis G Guijarro
Journal:  Curr Oncol       Date:  2022-03-30       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.